Proactive Investors - Run By Investors For Investors

Sahel Oncology using technology to battle aggressive cancers like lung and ovarian

Sahel Oncology CEO Michael A Nezami talked to Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. The drug developer is focused on oncology, with key products that have shown promising results in variety of cancer types. The company's main aim is to apply therapies that improve overall survival, rather than tumor size or progression free survival.

View full SAHEL profile View Profile

Sahel Oncology Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use